Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers

Biopharmaceutics and Drug Disposition

Volumn 29, Issue 2, 2008, Pages 91-101

  Ma, Qing ^a   Forrest, Alan ^a   Rosenkranz, Susan L ^b   Para, Michael F ^c   Yarasheski, Kevin E ^d   Reichman, Richard C ^e   Morse, Gene D ^a   Brizz, Barbara ^f   Cramer, Yoninah ^g   Walawander, Ann ^h   Ashton, Courtney ^h   Ferguson, Elaine ⁱ   de Caprariis, Pascal J ⁱ   Saah, Alfred J ⁱ   Becker, Mark ⁱ   Wire, Mary ^j   Shelton, Mark ^j  

^a UNIVERSITY AT BUFFALO   (United States)

^b HARVARD UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF ROCHESTER   (United States)

^f ACTG Operation Center

^g Statistical Data Analysis Center

^h Data Management Center

ⁱ DAIDS ^*

^j GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

Drug interactions; Efavirenz; HIV 1 protease inhibitors; Non nucleoside reverse transcriptase inhibitor; Pharmacokinetic modeling

Indexed keywords

AMPRENAVIR; CYTOCHROME P450 2B6; EFAVIRENZ; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; AEROBIC METABOLISM; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG POTENTIATION; EVENING DOSAGE; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; LINEAR SYSTEM; MALE; MORNING DOSAGE; NONLINEAR SYSTEM; NORMAL HUMAN; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SINGLE DRUG DOSE; STEADY STATE; VOLUNTEER;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 42049083341     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.597     Document Type: Article

References (34)

1. Morse GD, Rosenkranz S, Para MF, et al. Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals. Antimicrob Agents Chemother 2005; 49: 3373-3381.
2. Ma Q, Okusanya OO, Smith PF, et at. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin Drug Metab Toxicol 2005; 1: 473-485.
3. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306: 287-300.
4. Decker CJ, Laitinen LM, Bridson GW, et al. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998; 87: 803-807.
5. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44: 190-194.
6. Lillibridge JH, Liang BH, Kerr BM, et al. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 1998; 26: 609-616.
7. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106-111.
8. Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 2003; 47: 130-137.
9. Hammer SM, Vaida F, Bennett KK, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002; 288: 169-180.
10. Frerichs VA, DiFrancesco R, Morse GD. Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 787: 393-403.
11. Holland DT, DiFrancesco R, Stone J, et al. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother 2004; 48: 824-831.
12. Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999; 36: 289-304.
13. Martinez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 1036-1046.
14. Adkins JC, Noble S. Efavirenz. Drugs 1998; 56: 1055-1064; discussion 1065-1056.
15. Mutlib AE, Chen H, Nemeth GA, et al. Identification and chracterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos 1999; 27: 1319-1333.
16. Veldkamp AI, Harris M, Montaner JS, et al. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis 2001; 184: 37-42.
17. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids 2004; 18: 2391-2400.
18. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15: 1-5.
19. Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 2004; 319: 1322-1326.
20. DiCenzo R, Forrest A, Squires KE, et al. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2003; 47: 1929-1935.
21. Alsenz J, Steffen H, Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm Res 1998; 15: 423-428.
22. Lee CG, Gottesman MM. HIV-1 protease inhibitors and the MDR1 multidrug transporter. J Clin Invest 1998; 101: 287-288.
23. Profit L, Eagling VA, Back DJ. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999; 13: 1623-1627.
24. Adkins JC, Faulds D. Amprenavir. Drugs 1998; 55: 837-842; discussion 843-834.
25. Falloon J, Piscitelli S, Vogel S, et al. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis 2000; 30: 313-318.
26. Villani P, Regazzi MB, Castelli F, et al. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol 1999; 48: 712-715.
27. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003; 73: 20-30.
28. Kappelhoff BS, Huitema AD, Yalvac Z, et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet 2005; 44: 849-861.
29. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30-36.
30. Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 2002; 19: 1038-1045.
31. Mouly S, Lown KS, Kornhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002; 72:1-9.
32. Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with longterm efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005; 41: 1648-1653.
33. Wire MB, Ballow C, Preston SL, et al. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS 2004; 18: 897-907.
34. Sekar VJ, De Pauw M, Marien K, et al. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. Antiviral therapy 2007; 12: 509-514.